Breaking News

USAID support of 155 district disease surveillance and response units to federal and provincial health departments

Islamabad, December 16, 2020 (PPI-OT): In an auspicious ceremony today on 16th Dec 2020 at the MoNHSR C, the Special Advisor to Prime Minister for Health Dr Faisal Sultan while chairing the DDSRUs ceremony with participation of provincial Health Ministers and Provincial health authorities, expressed his gratitude to USAID and acknowledged that this historic support of establishing 155 DDSRUs all across Pakistan will go a long way in instituting the integrated disease surveillance system in Pakistan and will reduce the mortality and morbidity associated with infectious diseases with timely prevention, detection and response. All the provincial health departments and in charges of DDSRUs participated through virtual link.

Speaking at the ceremony, ED NIH Maj Gen Aamer Ikram explained the importance of such units which will now be connected to their respective provinces and ultimately to the federal epidemiology and disease surveillance division housed in NIH Islamabad for timely reporting on all infectious diseases, especially COVID-19 in these times. Dr Nabeela Ali COP IHSS-SD Activity gave a detailed presentation on theCOVID-19 support to provinces by USAID. At the occasion USAID Mission Director Ms Julie Koenen pledged to continue this rewarding partnership with the health system of Pakistan and articulated the vision of US Mission to improve the quality of life of people of Pakistan by investing in social sector.

For more information, contact:
Principal Information Officer,
Press Information Department (PID)
Tel: +92-51-9252323, +92-51-9252324
Fax: +92-51-9252325, +92-51-9252326
Email: piopid@gmail.com
Website: www.pid.gov.pk

Check Also

Zenas BioPharma Announces Upsized $200 Million Series C Financing to Advance Mid- and Late-Stage Immunology-Focused Clinical Development Programs

Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors Proceeds to support ongoing mid- to late-stage clinical development programs for Company’s lead I&I product candidate, obexelimab WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) — Zenas BioPharma, a global […]